Biology of advanced uveal melanoma and next steps for clinical therapeutics

A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma.

(2017) F. S. Hodi et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors.

(2017) M. S. Gordon et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).

(2017) Richard D. Carvajal et al.   JOURNAL OF CLINICAL ONCOLOGY

The Molecular Pathology of Melanoma: An Integrated Taxonomy of Melanocytic Neoplasia

(2014) Boris C. Bastian   Annual Review of Pathology-Mechanisms of Disease

Hippo-Independent Activation of YAP by the GNAQ Uveal Melanoma Oncogene through a Trio-Regulated Rho GTPase Signaling Circuitry

(2014) Xiaodong Feng et al.   CANCER CELL

Modulation of the Tumor Cell Phenotype by IFN-  Results in Resistance of Uveal Melanoma Cells to Granule-Mediated Lysis by Cytotoxic Lymphocytes

(2014) K. Hallermalm et al.   JOURNAL OF IMMUNOLOGY

Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials

(2014) Keith T Flaherty et al.   LANCET ONCOLOGY

The Phosphoinositide 3-Kinase   Selective Inhibitor BYL719 Enhances the Effect of the Protein Kinase C Inhibitor AEB071 in GNAQ/GNA11-Mutant Uveal Melanoma Cells

(2014) E. Musi et al.   MOLECULAR CANCER THERAPEUTICS

Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O)

(2013) Sander Kelderman et al.   ACTA ONCOLOGICA

Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma

(2013) M. Maio et al.   ANNALS OF ONCOLOGY

BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma

(2013) Katie A Matatall et al.   BMC CANCER

Clinical activity of ipilimumab for metastatic uveal melanoma

(2013) Jason J. Luke et al.   CANCER

Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+/M1 Phenotype that Orchestrates Effective T Cell Immunotherapy

(2013) Felix Klug et al.   CANCER CELL

Inhibition of both BRAF and MEK in BRAFV600E mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties

(2013) Patrick A. Ott et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic?

(2013) Jason John Luke et al.   EXPERT OPINION ON PHARMACOTHERAPY

Hypoxia inducible factor pathway inhibitors as anticancer therapeutics

(2013) Sarah K Burroughs et al.   Future Medicinal Chemistry

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study

(2013) Caroline Robert et al.   LANCET ONCOLOGY

Inhibition of Mutant GNAQ Signaling in Uveal Melanoma Induces AMPK-Dependent Autophagic Cell Death

(2013) G. Ambrosini et al.   MOLECULAR CANCER THERAPEUTICS

Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model

(2013) O. Surriga et al.   MOLECULAR CANCER THERAPEUTICS

Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease

(2013) Susan Achberger et al.   MOLECULAR IMMUNOLOGY

Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3

(2013) Marcel Martin et al.   NATURE GENETICS

Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma

(2013) J William Harbour et al.   NATURE GENETICS

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

SF3B1 Mutations Are Associated with Alternative Splicing in Uveal Melanoma

(2013) S. J. Furney et al.   Cancer Discovery

Structure–activity relationship of 2,2-dimethyl-2H-chromene based arylsulfonamide analogs of 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N-phenylbenzenesulfonamide, a novel small molecule hypoxia inducible factor-1 (HIF-1) pathway inhibitor and anti-cancer agent

(2012) Jiyoung Mun et al.   BIOORGANIC & MEDICINAL CHEMISTRY

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models

(2012) S V Holt et al.   BRITISH JOURNAL OF CANCER

Arylsulfonamide KCN1 Inhibits In Vivo Glioma Growth and Interferes with HIF Signaling by Disrupting HIF-1  Interaction with Cofactors p300/CBP

(2012) S. Yin et al.   CLINICAL CANCER RESEARCH

Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner

(2012) J. S. Khalili et al.   CLINICAL CANCER RESEARCH

Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance

(2012) G. Ambrosini et al.   CLINICAL CANCER RESEARCH

New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment

(2012) M. Ladanyi et al.   CLINICAL CANCER RESEARCH

Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP

(2012) Y. Liu-Chittenden et al.   GENES & DEVELOPMENT

Design and in Vitro Activities of N-Alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroarylsulfonamides, Novel, Small-Molecule Hypoxia Inducible Factor-1 Pathway Inhibitors and Anticancer Agents

(2012) Jiyoung Mun et al.   JOURNAL OF MEDICINAL CHEMISTRY

c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential

(2012) Xinqi Wu et al.   MELANOMA RESEARCH

A pilot study of sunitinib malate in patients with metastatic uveal melanoma

(2012) Amit Mahipal et al.   MELANOMA RESEARCH

Ipilimumab activity in advanced uveal melanoma

(2012) Muhammad Adnan Khattak et al.   MELANOMA RESEARCH

Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF- B Pathways

(2012) X. Wu et al.   MOLECULAR CANCER THERAPEUTICS

A Genome-wide RNAi Screen Reveals a Trio-Regulated Rho GTPase Circuitry Transducing Mitogenic Signals Initiated by G Protein-Coupled Receptors

(2012) Jose P. Vaqué et al.   MOLECULAR CELL

The Protein Kinase C Inhibitor Enzastaurin Exhibits Antitumor Activity against Uveal Melanoma

(2012) Xinqi Wu et al.   PLoS One

KCN1, a Novel Synthetic Sulfonamide Anticancer Agent: In Vitro and In Vivo Anti-Pancreatic Cancer Activities and Preclinical Pharmacology

(2012) Wei Wang et al.   PLoS One

Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512

(2012) Shailender Bhatia et al.   PLoS One

Loss of the Tumor Suppressor BAP1 Causes Myeloid Transformation

(2012) A. Dey et al.   SCIENCE

Binding Model for the Interaction of Anticancer Arylsulfonamides with the p300 Transcription Cofactor

(2012) Qi Shi et al.   ACS Medicinal Chemistry Letters

Influence of CD8+ T regulatory cells on intraocular tumor development

(2012) Kyle C. McKenna et al.   Frontiers in Immunology

Good news–bad news: the Yin and Yang of immune privilege in the eye

(2012) John V. Forrester et al.   Frontiers in Immunology

Ocular Immune Privilege and Ocular Melanoma: Parallel Universes or Immunological Plagiarism?

(2012) Jerry Y. Niederkorn   Frontiers in Immunology

Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors

(2011) Chalet Tan et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma

(2011) S. Landreville et al.   CLINICAL CANCER RESEARCH

Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin

(2011) A. A. Tarhini et al.   CLINICAL CANCER RESEARCH

Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers

(2011) M. H. Abdel-Rahman et al.   JOURNAL OF MEDICAL GENETICS

Design and Synthesis of Novel Small-Molecule Inhibitors of the Hypoxia Inducible Factor Pathway

(2011) Suazette Reid Mooring et al.   JOURNAL OF MEDICINAL CHEMISTRY

Germline mutations in BAP1 predispose to melanocytic tumors

(2011) Thomas Wiesner et al.   NATURE GENETICS

Germline BAP1 mutations predispose to malignant mesothelioma

(2011) Joseph R Testa et al.   NATURE GENETICS

Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma

(2010) Jo Eyles et al.   JOURNAL OF CLINICAL INVESTIGATION

In Aged Mice, Outgrowth of Intraocular Melanoma Depends on Proangiogenic M2-Type Macrophages

(2010) L. V. Ly et al.   JOURNAL OF IMMUNOLOGY

Phase 2 open-label study of weekly docosahexaenoic acid–paclitaxel in patients with metastatic uveal melanoma

(2010) Jade Homsi et al.   MELANOMA RESEARCH

Mutations inGNA11in Uveal Melanoma

(2010) Catherine D. Van Raamsdonk et al.   NEW ENGLAND JOURNAL OF MEDICINE

Influence of Immune Privilege on Ocular Tumor Development

(2010) Kyle C. McKenna et al.   OCULAR IMMUNOLOGY AND INFLAMMATION

Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas

(2010) J. W. Harbour et al.   SCIENCE

Defining the Human Deubiquitinating Enzyme Interaction Landscape

(2009) Mathew E. Sowa et al.   CELL

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications

(2008) Mario A. Economou et al.   ACTA OPHTHALMOLOGICA

O-Mel-Inib: A Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose Imatinib mesylate in metastatic uveal melanoma

(2008) Nicolas Penel et al.   INVESTIGATIONAL NEW DRUGS

Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis

(2008) Shu-Hong Chang et al.   MELANOMA RESEARCH

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

(2008) Catherine D. Van Raamsdonk et al.   NATURE